Leerink Partnrs Comments on Q32 Bio FY2029 Earnings

Q32 Bio Inc. (NASDAQ:QTTB) – Equities researchers at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Q32 Bio in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($0.75) per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share.

A number of other research firms also recently weighed in on QTTB. BMO Capital Markets dropped their target price on Q32 Bio from $64.00 to $22.00 and set an “outperform” rating for the company in a report on Thursday, December 12th. Oppenheimer lowered their target price on shares of Q32 Bio from $80.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Wells Fargo & Company reissued an “equal weight” rating and set a $16.00 price target (down previously from $95.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Piper Sandler dropped their price objective on Q32 Bio from $85.00 to $20.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, Leerink Partners reissued a “market perform” rating and set a $9.00 target price (down from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Q32 Bio Stock Performance

NASDAQ:QTTB opened at $3.16 on Friday. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.61. The stock has a 50 day simple moving average of $6.86 and a 200 day simple moving average of $29.27. Q32 Bio has a 1-year low of $2.90 and a 1-year high of $53.79. The stock has a market cap of $38.49 million, a P/E ratio of -0.22 and a beta of -0.32.

Hedge Funds Weigh In On Q32 Bio

A number of institutional investors have recently modified their holdings of QTTB. Values First Advisors Inc. bought a new position in Q32 Bio in the third quarter valued at about $33,000. BNP Paribas Financial Markets grew its holdings in shares of Q32 Bio by 199.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company’s stock valued at $58,000 after purchasing an additional 864 shares during the last quarter. MetLife Investment Management LLC acquired a new position in Q32 Bio during the 3rd quarter worth approximately $159,000. Franklin Resources Inc. bought a new position in Q32 Bio in the 3rd quarter valued at approximately $225,000. Finally, Barclays PLC grew its stake in shares of Q32 Bio by 105.2% during the third quarter. Barclays PLC now owns 10,443 shares of the company’s stock worth $465,000 after buying an additional 5,353 shares during the last quarter. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.